文献速递系统性红斑狼疮

系统性红斑狼疮B细胞清除的为什么、做什么、谁来做与何时做:生物学依据、患者分层与演变中的治疗模式

The why, what, who and when of B cell depletion in systemic lupus erythematosus: biological rationale, patient stratification and evolving therapeutic modalities.
PubMed 文献 · Rheumatology (Oxford) · 2026-01-01

该综述阐述SLE中B细胞作为抗原呈递细胞、细胞因子产生者和自身抗体分泌浆细胞前体驱动免疫环路,抗CD20单抗验证了B细胞为治疗靶点但存在组织清除不完全、长寿命浆细胞持续和BAFF驱动再聚集等限制,新一代抗CD20、双特异性T细胞衔接器和CAR-T疗法展现前景但患者选择、时机和模式仍待明确。

要点

  • B细胞通过抗原呈递、细胞因子产生和自身抗体分泌驱动SLE免疫环路,治疗旨在打断自我强化环路而非仅降低抗体滴度。
  • 抗CD20单抗临床经验验证B细胞为靶点,但暴露组织清除不完全、长寿命浆细胞持续和BAFF驱动再聚集等生物学限制。
  • 新一代抗CD20、双特异性T细胞衔接器和CAR-T疗法展现前景,但哪些患者用何种模式及何时治疗仍待明确。

核心结论

  • 靶向B细胞旨在打断SLE中自我强化的免疫环路而非单纯降低自身抗体滴度,新一代B细胞清除疗法展现前景但患者选择、时机和治疗模式仍待明确。

研究设计与样本

  • 综述评估当前B细胞靶向治疗格局,重点关注患者选择、治疗时机和治疗类型。

主要发现

  • B细胞在SLE中作为抗原呈递细胞、细胞因子产生者和自身抗体分泌浆细胞前体发挥作用。
  • 抗CD20单抗临床经验验证B细胞为治疗靶点,同时暴露组织清除不完全、长寿命浆细胞持续和BAFF驱动B细胞再聚集等关键生物学限制。
  • 新一代抗CD20单抗、双特异性T细胞衔接器和CAR-T细胞疗法已显示前景。

临床怎么用

  • 临床选择B细胞清除治疗时需综合考虑患者选择、治疗时机和治疗模式,而非仅关注降低自身抗体滴度。
  • 需认识到抗CD20单抗存在组织清除不完全、长寿命浆细胞持续和BAFF驱动再聚集等限制。

局限性

  • 哪些患者应接受何种B细胞靶向治疗模式以及治疗在疾病病程中的时机仍不明确。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Systemic lupus erythematosus (SLE) is driven by interconnected immune circuits in which B cells function as antigen-presenting cells, cytokine producers and precursors of autoantibody-secreting plasma cells. Therapeutic targeting of B cells aims to disrupt these self-reinforcing circuits rather than simply reduce autoantibody titres alone. Clinical experience with anti-CD20 monoclonal antibodies has validated B cells as therapeutic targets, while exposing key biological constraints, including incomplete tissue depletion, persistence of long-lived plasma cells, and BAFF-driven B cell repopulation. Recent advances including next-generation anti-CD20 monoclonal antibodies, bispecific T cell engagers and chimeric antigen receptor (CAR) T cell therapies have shown promise but questions remain relating to which patients should be treated with what modality of therapy and when this should be timed within the disease course. Herein, we evaluate the current landscape of B cell targeting therapies with particular focus on patient selection, timing of therapy and type of treatment.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Wincup C, Gatto M, Scherlinger M, et al. The why, what, who and when of B cell depletion in systemic lupus erythematosus: biological rationale, patient stratification and evolving therapeutic modalities. Rheumatology (Oxford). 2026. PMID: 42599215. doi:10.1093/rheumatology/keag416

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。